Search

Danaher Corp

Закрыт

СекторЗдравоохранение

202.44 -0.76

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

201

Макс.

203.87

Ключевые показатели

By Trading Economics

Доход

-159M

870M

Продажи

314M

6.3B

P/E

Средняя по отрасли

36.476

57.002

Прибыль на акцию

1.94

Дивидендная доходность

0.7

Рентабельность продаж

13.887

Сотрудники

58,000

EBITDA

-364M

1.1B

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+7.79% upside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

0.70%

2.22%

Следующий отчет о доходах

20 окт. 2026 г.

Дата следующей выплаты дивидендов

30 окт. 2026 г.

Следующая эксдивидендная дата

25 сент. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

4.8B

147B

Предыдущая цена открытия

203.2

Предыдущая цена закрытия

202.44

Новостные настроения

By Acuity

23%

77%

79 / 340 Рейтинг в Healthcare

Danaher Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 авг. 2026 г., 20:06 UTC

Danaher Corp's shares are lower amid concerns over a surprising drop in U.S. retail sales, which fell 0.6% in July against expectations.

13 авг. 2026 г., 23:31 UTC

Danaher Corp shares rose in after-market trading, buoyed by unchanged producer prices in July and easing inflation concerns affecting investor sentiment.

12 авг. 2026 г., 23:46 UTC

Danaher Corp. shares were roughly flat in after-market trading, maintaining a position above its 20-day moving average and near the upper end of its one-month range.

10 авг. 2026 г., 19:42 UTC

Danaher Corp shares are higher today, supported by a broader rise in the Life Sciences Tools & Services sub-sector. The stock remains above its 20-day moving average.

7 авг. 2026 г., 19:36 UTC

News

Danaher Corp's stock is higher today, supported by significant insider transactions. The CFO and Executive Vice President reported acquiring substantial stock options.

6 авг. 2026 г., 20:02 UTC

Shares of Danaher Corp are higher, reflecting broader market gains since Wednesday's close. The stock is near the upper end of its one-month range.

5 авг. 2026 г., 19:51 UTC

Danaher Corp shares are higher today, supported by gains in the Life Sciences Tools & Services sub-sector. The stock has shown notable volatility during the session.

4 авг. 2026 г., 23:01 UTC

Danaher Corp shares are higher in after-market trading, supported by broader market optimism and easing oil prices contributing to favorable inflation expectations.

3 авг. 2026 г., 22:51 UTC

News

Danaher Corp appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026. Shares are trading higher in after-market hours.

31 июл. 2026 г., 23:01 UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

30 июл. 2026 г., 18:01 UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

29 июл. 2026 г., 23:01 UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

28 июл. 2026 г., 23:01 UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

27 июл. 2026 г., 23:16 UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

24 июл. 2026 г., 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23 июл. 2026 г., 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22 июл. 2026 г., 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21 июл. 2026 г., 19:41 UTC

News
Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20 июл. 2026 г., 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Сравнение c конкурентами

Изменение цены

Danaher Corp Прогноз

Целевая цена

By TipRanks

7.79% рост

Прогноз на 12 месяцев

Средняя 219.78 USD  7.79%

Максимум 240 USD

Минимум 195 USD

Основано на мнении 20 аналитиков Wall Street, спрогнозировавших целевые цены для Danaher Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

20 ratings

17

Покупка

3

Удержание

0

Продажа

Настроения

By Acuity

79 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat